Gemelli Biotech Launches Novel Breath Test

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

October 27, 2020

Gemelli Biotech, Los Angeles and Raleigh based, has announced the launch of a novel breath test called trio-smart™ that provides a more complete fermented gas profile of a patient’s microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose).

Gemelli Biotech notes trio-smart™ is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab.

While hydrogen and methane breath tests have been common, hydrogen sulfide – the third important fermentable gas in the human microbiome – has been known to have toxicity at elevated levels, also affecting the GI tract; however, the measurement of hydrogen sulfide levels in the breath of patients has previously been unavailable to physicians and researchers due to technological challenges. As a result, many patients with serious GI symptoms appear “normal” on hydrogen and methane breath tests.

Now, the culmination of years of research, a breakthrough by scientists at the Medically Associated Science and Technology (MAST) program at Cedars-Sinai has led to the development of cutting-edge technology that can accurately capture, transport, and measure hydrogen sulfide in the breath of patients. The patent rights covering the technology are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center to Gemelli Biotech.

“An estimated 25% of patients who appear normal on hydrogen and methane tests could have elevated hydrogen sulfide levels and associated GI complications,” says Dr. Mark Pimentel, executive director of MAST. “These patients were being unrecognized by previous tests that did not measure hydrogen sulfide.”

He adds that hydrogen, methane, hydrogen sulfide, and the organisms that produce these gases are linked in a complex interplay.1 “These gases do not act independently of each other in the microbiome. Therefore, it is impossible to get a full picture of a patient’s fermented gas profile without measuring all three gases.”

Gemelli Biotech previously partnered with MAST to bring their second-generation blood test for IBS called ibs-smart™ to the market. Building on this successful partnership, Gemelli will be offering trio-smart™ as a mail-in kit-based test that physicians can order directly from the trio-smart™ website.

No other breath test offers the measurement of all three gasses. Matt Mitcho, CEO of Gemelli Biotech, says this is in line with Gemelli’s commitment to putting patients first.

“We are focused on making the process of breath testing as easy and effective as possible. With a user-friendly sample collection system and testing technology that is best in class for accuracy, trio-smart™ has the potential to benefit countless patients.”


1. Singer-Englar, T., Rezaie, A., Gupta, K. et al. (2018). Competitive Hydrogen Gas Utilization by Methane- and Hydrogen Sulfide-Producing Microorganisms and Associated Symptoms: Results of a Novel 4-Gas Breath Test Machine. [Abstract]. Gastroenterology. DOI: https://doi.org/10.1016/S0016-5085(18)30625-5.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.